

## The Pain Visual Analog Scale: Linear or Nonlinear?

*To the Editor:*—I have spent some time considering the conclusions reached by Aubrun *et al.*<sup>1</sup> in their study investigating the relationship between the pain visual analogue scale (VAS) and morphine requirements in the postanesthesia care unit. They demonstrated that the Hill equation could be used to derive a sigmoid relationship between the pain VAS and morphine dosage, and concluded that this relationship is not linear. In their discussion, they referred to an earlier study in which I and colleagues had found a linear relationship between pain intensity and the pain VAS,<sup>2</sup> and they seemed to suggest that their study contradicted our earlier results.

The results of the Aubrun *et al.* study could have been readily predicted from their methodology, in that the Hill equation is a standard approach used to generate a sigmoid curve using population pharmacokinetics. This approach generates a typical dose-response curve. Such a curve could be derived for the dose of a hypotensive drug and blood pressure, or the dose of a sedative drug and hypnotic state. Yet, the effect of interest—be it blood pressure, hypnotic state, or pain intensity—can still be linear phenomena. The results of the study data analyzed by the authors do not preclude the possibility that the pain VAS has ratio scale properties and is linear. In fact, if the pain VAS is linear then it would have a sigmoid relationship with morphine dosage.

I have one other concern regarding the conclusions drawn by the

authors. In their Methods, they arbitrarily defined “severe pain” as when the patient received a total dose of intravenous morphine greater than 0.15 mg/kg. Because they found an association between an initial VAS score of 70 or greater (VAS<sub>70</sub>) and morphine dosage greater than 0.15 mg/kg, they concluded that VAS<sub>70</sub> was indicative of severe pain. But VAS<sub>70</sub> itself may not signify severe pain. Opioid dose-response has substantial interindividual variability, with a five- to tenfold range in requirements. Patients may fail to respond to a specific dose not because they have greater pain intensity but because they have had a lesser response to that dose.

**Paul S. Myles, M.B., B.S., M.P.H., M.D., F.C.A.R.C.S.I., F.A.N.Z.C.A.** Alfred Hospital, Melbourne, Australia. p.myles@alfred.org.au.

### References

1. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B: Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. *ANESTHESIOLOGY* 2003; 98: 1415–21
2. Myles PS, Troedel S, Boquest M, Reeves M: The pain visual analog scale: Is it linear or nonlinear? *Anesth Analg* 1999; 89:1517–20

(Accepted for publication November 20, 2003.)

## Analgesic Evaluation in Postoperative Patients

*To the Editor:*—We read with interest the study reported by Aubrun *et al.*<sup>1</sup> in the June issue of *ANESTHESIOLOGY* as well as the accompanying editorial.<sup>2</sup>

This study is analysis of routine data collected by nursing staff. The postanesthesia care unit nurses in this study<sup>1</sup> followed a routine protocol for the administration of morphine. Most hospitals have standard operating procedures for morphine administration in the PACU. In the study by Auburn *et al.*,<sup>1</sup> nurses were instructed to ask the patients about their pain and helped them perform a visual analog scale (VAS) every 5 min. Then they administered a 2- or 3-mg dose of morphine (depending on body weight) until adequate pain relief occurred (defined as a VAS < 30). It is very hard to perform 5 to 20 consecutive measurements of respiratory rate, oxygen saturation, arterial blood pressure, Ramsay sedation score, and heart rate while administering morphine every 5 min unless one has no other patient care responsibility. The authors<sup>1</sup> also mentioned that they had discovered that in approximately 17% of the patients, the VAS was not used but instead a verbal or subjective behavioral scale (not defined) was used to collect pain information. Subjects were excluded from the analysis if their pain was not relieved and they required rescue medication. No information is provided regarding what constituted inadequate analgesia requiring rescue. A major limitation of this study is its retrospective nature; therefore, the data provided should be interpreted cautiously.

The authors state that 3,045 patients were analyzed. An assumption is made that all 3,045 patients had relief of pain (VAS < 30) following treatment with morphine, as no information is provided to the contrary. The overall success rate reported by Aubrun *et al.* is impressive (> 96%). Their table 1 shows that in 39% of patients, severe pain (VAS > 70) was reduced to mild pain (VAS < 30) with 10 mg or less of morphine (in a 70-kg subject). This appears, on the basis of our experience, to be a rather

unexpectedly high success rate in patients with severe postoperative pain. We have been evaluating dose-response of morphine in an ongoing study of patients recovering from total abdominal hysterectomy. In our study, patients are randomized to receive either 12 mg or 21 mg of morphine (3 mg every 3 min) in the PACU, in a double-blind manner. We also defined desired relief as a verbal analog scale of 3 out of 10. We have studied 10 patients so far (unpublished data) and have not achieved the desired relief in any. In another study, we evaluated the analgesic effect of a single 7.5-mg dose of morphine in a double-blind study in patients with lower abdominal procedures and could not measure much analgesia until rescue 10–15 min later. The authors<sup>1</sup> evaluated a diverse group of patients. The data, however, were not analyzed on the basis of surgical type to minimize variations in baseline postoperative pain scores. The authors should have provided basic descriptive statistics such as the number of doses of morphine needed to achieve pain relief based on the initial pain score, type of surgery, and percentage of failure and success, as well as the presence of side effects (if any) and the influence of gender and age. It is equally important to measure the effect of morphine on the affective component of pain, as some patients feel relief despite no change in the intensity of pain.

The editorial<sup>2</sup> accompanying this manuscript stresses that the difference in various procedures translates into lack of standardization of intraoperative anesthetics. We believe diversity of cases reflects a source of baseline variability in pain scores. Furthermore, the editorial states that “opioids side effects exert a major impact on the course of postoperative recovery and limit effective opioids titration in many cases.” We believe that in the majority of cases it is the fear of side effect that limits effective opioids titration. Indeed, at 2 and 5 min after administration of a single 7.5-mg dose of morphine, we observed no significant hemodynamic change.

Although our European counterparts have reported better success with larger doses, even these doses may not be sufficiently large. Evaluation of higher doses (*i.e.*, 5 mg) at 3- to 5-min intervals may demonstrate a better relief profile in most patients. The frequency of adverse events should increase with dose; the anticipated occurrence of these side effects, however, may be exaggerated because of our lack of experience. Clinicians are often too concerned about the respiratory effect of rather small doses of morphine (1–2 mg). In some of our patients undergoing abdominal procedures, tachypnea may have represented intentional defense against pain (to avoid deep breaths). We have noticed a significant drop in respiratory rate to a more normal range after relief of pain in some of these patients.

We continue to believe that postoperative pain is undertreated because of the caregiver's fear and lack of experience. It has been known for quite some time that a VAS of 70 or 80 should be considered severe pain, and that severe pain requires more morphine for treatment than mild or moderate pain. Although postoperative treatment

should be individualized, the safety and efficacy of higher doses of morphine must be determined prospectively in patients with moderate-to-severe postoperative pain.

**Ghassem E. Larijani, Pharm.D.,\* Michael E. Goldberg, M.D.**  
\* University of Medicine and Dentistry of New Jersey, Cooper Hospital, Camden, New Jersey. larijage@umdnj.edu

## References

1. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B: Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. *ANESTHESIOLOGY* 2003; 98: 1415–21
2. Berde CB, Brennan TJ, Raja SN: Opioids: More to learn, improvements to be made (editorial). *ANESTHESIOLOGY* 2003; 98:1309–12

(Accepted for publication November 20, 2003.)

Anesthesiology, 2004; 100:745

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

**In Reply:**—We thank our colleagues for their comments and criticisms of our study,<sup>1</sup> and we wish to offer the following responses.

First, it is not hard to measure respiratory rate, oxygen saturation, and arterial blood pressure during morphine titration because monitors perform those functions well. Moreover, determination of Ramsay score is also very rapid, because an awake patient who is able to rate his or her visual analog scale (VAS) can be easily quoted 1 on the Ramsay score. Concerning the verbal and subjective behavioral scale used by our nurses, the reader could refer to our recent published study.<sup>2</sup> The definition of inadequate analgesia requiring rescue was subjective: the anesthesiologist decided to stop morphine titration and use another analgesic technique, usually when more than 10–15 bolus of morphine were administered.

We do not accept the term “retrospective” used by Larijani and Goldberg. Indeed, the design of our study was clearly defined after a pilot study,<sup>3</sup> a special data sheet was implemented (although this data sheet is now that used in routine practice in our unit), and all consecutive patients who fulfilled the criteria for inclusion and did not fulfill the criteria of exclusion were included. Thus, we think that this study was prospective.

We agree with Larijani and Goldberg that we need more information on the relationship between morphine requirement and the type of surgery. The influence of gender is real, but its magnitude seems not to be very important. Last, we previously demonstrated that age does not modify morphine requirement during intravenous morphine titration,<sup>4,5</sup> whereas subcutaneous morphine requirement during the initial 24 h is significantly decreased in elderly patients.<sup>5</sup> Larijani and Goldberg suggest that higher-bolus doses could be more rapidly efficient. We agree with this hypothesis, but the incidence of adverse outcomes may also increase. Only a randomized study could provide the response, and we have begun such a study.

Larijani and Goldberg report that their patients who had abdominal hysterectomy required a higher dose of morphine. In our study, 33 women underwent abdominal hysterectomy and they actually required  $14 \pm 8$  mg ( $0.23 \pm 0.14$  mg/kg) morphine during intravenous titration, indicating that this surgery induced severe postoperative pain requiring a greater dose of morphine. However, comparison of the morphine doses during postoperative intravenous titration must be done cautiously, because the anesthetic regimen during the preoperative period, including the type and dose of opioids administered, may markedly interfere with that dose. The interest of our study is only to provide data from a large population to help to recognize some important relationships between the measurement of pain using VAS and morphine requirements. Further studies are required to precise the

preoperative and postoperative variables associated with morphine dose in the postoperative period, as recently studied by Dahmani *et al.*<sup>6</sup>

In our opinion, the definition of severe pain (*i.e.*, VAS > 70) may not be very useful for a given patient. In contrast, we have explained that this definition may help to identify a population of patients that could benefit from morphine titration in less supervised clinical conditions, such as emergency medicine, or may help to stratify the severity of pain during clinical trials.<sup>1</sup>

We do not agree with the comment from Dr. Myles concerning the linear *versus* sigmoid nature of the relationship between visual analog scale and morphine dose. In our study, we provided several statistical points of evidence that this curve is better described using a sigmoid curve than a straight line. These data include both the initial (30–40) and final (80–100) parts of the VAS range. The important question is whether or not this relationship reflects the VAS-pain relationship. In our study, we suggest that measuring the morphine dose required to obtain pain relief may be another way to assess the severity of pain. However, we agree that we did not take into account the complex nature of pain, which cannot be summarized only by its intensity, and that opioid-dose response has substantial interindividual variability.

In conclusion, we hope that our recent studies on intravenous morphine titration<sup>1–5</sup> will favor the development on more clinical research on this important topic.

**Frédéric Aubrun, M.D., Bruno Riou, M.D., Ph.D.\*** \* CHU Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France. bruno.riou@psl-hop-paris.fr

## References

1. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B: Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. *ANESTHESIOLOGY* 2003; 98: 1415–21
2. Aubrun F, Paqueron X, Langeron O, Coriat P, Riou B: What pain scales do nurses use in the postanesthesia care unit? *Eur J Anaesthesiol* 2003; 20:745–9
3. Aubrun F, Monsel S, Langeron O, Coriat P, Riou B: Postoperative titration of intravenous morphine. *Eur J Anaesthesiol* 2001; 18:159–65
4. Aubrun F, Monsel S, Langeron O, Coriat P, Riou B: Intravenous morphine titration in the elderly. *ANESTHESIOLOGY* 2002; 96:17–23
5. Aubrun F, Bunge D, Langeron O, Saillant G, Coriat P, Riou B: Postoperative morphine consumption in the elderly patient. *ANESTHESIOLOGY* 2003; 99:160–5
6. Dahmani S, Dupont H, Mantz J, Desmonts JM, Keita H: Predictive factors of early morphine requirements in the post-anesthesia care unit (PACU). *Br J Anaesth* 2001; 87:385–9

(Accepted for publication November 20, 2003.)

Anesthesiology 2004; 100:746

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams &amp; Wilkins, Inc.

## Is Overestimation of Bispectral Index in Sedated Intensive Care Unit Patients Only Related to Electromyographic Activity?

**To the Editor:**—Based on previous research reporting that electromyographic activity has been shown to elevate the bispectral index (BIS) in patients not receiving neuromuscular blockade, Vivien *et al.*<sup>1</sup> investigated the magnitude of the decrease in BIS value following administration of neuromuscular blocking drugs (NMB) in sedated intensive care unit patients. They concluded that BIS might be lower with paralysis for an equivalent degree of sedation because of high muscular activity. Therefore, Vivien *et al.*<sup>1</sup> ascribe the BIS value modification only to suppression of muscular activity due to the use of NMB. Nevertheless, the effect of administration of a neuromuscular blocker on BIS and electromyographic activity was highly variable among the 45 patients studied, and in 13 of the 45 patients there was no change in BIS range assessment. These considerations could support the hypothesis that BIS modification may be related not only to muscular activity suppression but also to NMB properties.

NMB are reported to potentiate the effects of anesthetics. Despite the emphasis that all NMB are completely devoid of analgesic properties,<sup>2</sup> some elicit analgesia. Laudanosine, the atracurium and cisatracurium metabolite, elicits dose-dependent analgesia in the mouse, attenuated by coadministration of  $\mu$ 1- and  $\mu$ 2-selective antagonists, indicating a  $\mu$ -related mechanism for analgesic properties of laudanosine.<sup>3</sup> A cross-tolerance between laudanosine and morphine has also been observed.<sup>3</sup> Moreover, at clinical concentrations reported in cerebrospinal fluid, atracurium and laudanosine are able to activate the central  $\alpha_4\beta_2$  nicotinic acetylcholine subtype receptors.<sup>4</sup> Agonists for these receptors showed analgesic activity. Epibatidine, a potent ligand identified at the  $\alpha_4\beta_2$  nicotinic acetylcholine receptor subtype, displayed a potent nicotinic activity and a strong nicotinic analgesic effect.<sup>5</sup> Taken together, these data indicate that the coadministration of the NMB atracurium or cisatracurium in sedated patients could potentiate the effects of midazolam and sufentanil sedation, and therefore decrease BIS value. This hypothesis is also consistent with a study

reporting that mivacurium, a NMB without analgesic properties, does not alter hypnotic level during propofol anesthesia.<sup>6</sup>

Nevertheless, it is not possible to support or deny the suggested hypothesis; interestingly, the NMB used in the study of Vivien *et al.*<sup>1</sup> were not reported. A list of NMB administered to the patients could maybe offer an aid, pro or contra.

The clinical relevance is that the modification of BIS detected by Vivien *et al.*<sup>1</sup> in sedated intensive care unit patients after administration of NMB may be related not only to muscular activity block, as masterfully demonstrated, but also to other cofactors related to NMB or their metabolites' properties.

**Vincenzo Fodale, M.D.,\* Letterio B. Santamaria, M.D.** \* University of Messina, Policlinico Universitario "G. Martino," Messina, Italy. vfodale@unime.it

## References

1. Vivien B, Di Maria S, Ouattara A, Langeron O, Coriat P, Riou B: Overestimation of bispectral index in sedated intensive care unit patients revealed by administration of muscle relaxant. *ANESTHESIOLOGY* 2003; 99:9-17
2. Prielipp RC, Coursin DB: Applied pharmacology of common neuromuscular blocking agents in critical care. *New Horiz* 1994; 2:34-47
3. Fodale V, Santamaria LB: Laudanosine, an atracurium and cisatracurium metabolite. *Eur J Anaesth* 2002; 19:466-73
4. Fodale V, Santamaria LB: The possible neuroprotective effect of laudanosine, an atracurium and cisatracurium metabolite (letter). *Acta Anaesthesiol Scand* 2003; 47:780-1
5. Belluardo N, Mudo G, Blum M, Fuxe K: Central nicotinic receptors, neurotrophic factors and neuroprotection. *Behav Brain Res* 2000; 113:21-34
6. Greif R, Greenwald S, Schweitzer E, Laciny S, Rajek A, Caldwell JE, Sessler DI: Muscle relaxation does not alter hypnotic level during propofol anesthesia. *Anesth Analg* 2002; 94:604-8

(Accepted for publication November 25, 2003.)

Anesthesiology 2004; 100:746-7

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams &amp; Wilkins, Inc.

**In Reply:**—We appreciate the interest of Drs. Fodale and Santamaria in our article examining the decrease in bispectral index (BIS) following the administration of a neuromuscular blocker<sup>1</sup> and would like to reply to their comments. Above all, we must correct a mistake in the letter: The neuromuscular blocker used in our study was clearly reported as 0.5 mg/kg atracurium in every patient studied. Otherwise, we think that the analysis of the authors is simply invalid for several reasons.

First, Peat *et al.*<sup>2</sup> reported that the prolonged use of atracurium is not associated with excessive accumulation of laudanosine, so long as the renal and hepatic functions are normal. On the other hand, Grigore *et al.*<sup>3</sup> also reported that laudanosine accumulation may occur in patients with both fulminant hepatic and renal failures, but it is not associated with any measurable central neurologic effect. In our study, we investigated either a single standard dose of atracurium or the beginning of a long-term administration. Therefore, we do not think that we could have observed central neurologic effects due to high concentrations of laudanosine in our patients.

Second, an analgesia-mediated property was described experimentally for laudanosine through a  $\mu$ 1 mechanism<sup>4</sup> and stimulation of the central  $\alpha_4\beta_2$  nicotinic acetylcholine receptor.<sup>5</sup> However, BIS is less influenced by analgesic than by sedative drugs,<sup>6</sup> and consecutive BIS change because of laudanosine should have been very limited.

Third, the authors reported in a recent review that data about the evidence of the depressive effects of laudanosine on the central nervous system in humans are not yet available.<sup>7</sup> They also reported that the laudanosine administration would either stimulate the central nervous system or have convulsive effects.<sup>8,9</sup> Such effects would logically and expectedly result in an increase in BIS values,<sup>10</sup> in contrast to that suggested in the letter from the authors.

Finally, even if a BIS decrease following atracurium administration would have been due to the sedative effect of laudanosine produced after atracurium administration, it seems unlikely that BIS recovery after laudanosine elimination would have been exactly parallel to electromyographic activity recovery after atracurium elimination, as observed in our patients.

**Benoît Vivien, M.D., Ph.D.,\* Bruno Riou, M.D., Ph.D.** \* CHU Pitié-Salpêtrière, Paris, France. benoit.vivien@psl.ap-hop-paris.fr.

## References

1. Vivien B, Di Maria S, Ouattara A, Langeron O, Coriat P, Riou B: Overestimation of Bispectral Index in sedated intensive care unit patients revealed by administration of muscle relaxant. *ANESTHESIOLOGY* 2003; 99:9-17
2. Peat SJ, Potter DR, Hunter JM: The prolonged use of atracurium in a patient with tetanus. *Anaesthesia* 1988; 43:962-3

Anesthesiology, V 100, No 3, Mar 2004



3. Grigore AM, Brusco L Jr, Kuroda M, Koorn R: Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion. *Crit Care Med* 1998; 26:180-3
4. Katz Y, Weizman A, Pick CG, Pasternak GW, Liu L, Fonia O, Gavish M: Interactions between laudanosine, GABA, and opioid subtype receptors: Implication for laudanosine seizure activity. *Brain Res* 1994; 646:235-41
5. Tassonyi E, Fathi M, Hughes GJ, Chiodini F, Bertrand D, Muller D, Fuchs-Buder T: Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage. *Acta Anaesthesiol Scand* 2002; 46:1236-41
6. Johansen JW, Sebel PS: Development and clinical application of electroencephalographic bispectrum monitoring. *ANESTHESIOLOGY* 2000; 93:1336-44
7. Fodale V, Santamaria LB: Laudanosine, an atracurium and cisatracurium metabolite. *Eur J Anaesthesiol* 2002; 19:466-73

8. Beemer GH, Bjorksten AR, Dawson PJ, Crankshaw DP: Production of laudanosine following infusion of atracurium in man and its effects on awakening. *Br J Anaesth* 1989; 63:76-80
9. Scheepstra GL, Vree TB, Crul JF, van de Pol F, Reekers-Ketting J: Convulsive effects and pharmacokinetics of laudanosine in the rat. *Eur J Anaesthesiol* 1986; 3:371-83
10. White PF, Rawal S, Recart A, Thornton L, Little M, Stool L: Can the bispectral index be used to predict seizure time and awakening after electroconvulsive therapy? *Anesth Analg* 2003; 96:1636-9

(Accepted for publication November 25, 2003.)

Anesthesiology 2004; 100:747

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

## Management of Patient Body Temperature Is Challenging

*To the Editor:*—We thank Gali *et al.* for their description of what they consider to be a pressure/burn injury following the use of the Allon thermoregulation system.<sup>1</sup> Management of patient body temperature and successful maintenance of normothermia in such a procedure is challenging and, as noted by the authors themselves, the patient maintained normothermia and her temperature at the end of the procedure was 36.3°C.

The incidence of pressure ulcers during surgery is well documented in the literature. Overall incidence is around 8%, depending on type of surgical procedure and length of surgery. The incidence rate is positively correlated to the length of the procedure and exceed 13% in procedures lasting longer than 7 h.<sup>2-5</sup>

As Gali *et al.* state, this patient had numerous risk factors that predisposed her to pressure-related injury during the operative procedure, including prolonged surgery (6.5 h), advanced age, severe muscle wasting, poor nutritional status, end-stage liver disease, and intraoperative hypotension. We therefore beg to differ with the authors' favoring the injury as being primarily due to a burn. This interpretation is based on the surgeon's impression and on the patient's postoperative complaint of a burning sensation in the affected area.

It is nearly impossible to differentiate by observation alone whether a skin lesion is due to pressure or a burn, whereas a burning sensation is certainly not specific to burns and can be caused by different kinds of lesions. Moreover, water temperature in the garment is limited to maximum of 40.8°C, so a contact burn due to overheating is virtually impossible.<sup>6-7</sup> The Allon system itself was checked and found to be functioning properly.

In anticipated long-duration procedures and in chronically ill, high-risk patients, the usual precautions of meticulous attention to adequate

relief of pressure points should be followed. MTRE's user's manual and leaflet guidelines specifically recommend the use of protective means for pressure sores between the operating table and the ThermoWrap. Furthermore, using ThermoWrap reduces the risk of developing such skin lesions because the Allon system is equipped with a unique pressure relief algorithm, the purpose of which is to address the known phenomena of intraoperative pressure ulcers.

MTRE's main goal is to provide normothermia in anesthetized patients with maximal patient safety. Despite our excellent track record (< 0.5% reported skin injury out of ≥ 10,000 procedures), MTRE is continuously looking into new concepts, materials, and wraps that will improve patient safety even more.

**Ram Y. Sharon, B.Sc.** MTRE Advanced Technologies, Ltd., Or Akiva Industrial Park, Israel. [mtre@mtre.co.il](mailto:mtre@mtre.co.il).

## References

1. Gali B, Findlay JY, Plevak DJ: Skin injury with the use of a water warming device. *ANESTHESIOLOGY* 2003; 98:1509-10
2. Aronovitch SA: Intraoperatively acquired pressure ulcer prevalence: A national study. *Adv Wound Care* 1998; 11:8-9
3. Aronovitch SA: Intraoperatively acquired pressure ulcer prevalence: A national study. *J Wound Ostomy Continence Nursing* 1999; 26:130-6
4. Kemp MG, Keithley JK, Smith DW, Morreale B: Factors that contribute to pressure sores in surgical patients. *Res Nurs Health* 1990; 13:293-301
5. Schultz A: Etiology and incidence of pressure ulcers in surgical patients. *AORN J* 1999; 70:434-49
6. Stewart TP: When a burn is not a burn. *Int J Dermatol* 1998; 37:729-32
7. Stewart TP, Magnano SJ: Burns or pressure ulcers in the surgical patient? *Decubitus* 1988; 1:36-40

(Accepted for publication September 28, 2003.)

Anesthesiology 2004; 100:747

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

*In Reply:*—A 13% incidence of pressure sores quoted by Dr. Sharon is much higher than we see in our liver transplant population. In the past 8 yr, this is the only case of skin injury documented in our liver transplant patients. The skin injury that our patient developed had the imprint of the water-warming device on it, removing any doubt that the warmer was involved in the injury. The occurrence of this injury despite proper placement and functioning of the device suggests that adjustments to the Allon system may be necessary.

It is true that our patient had risk factors predisposing her to skin injury, but we were concerned about temperature maintenance because of these factors. If she had been healthy and well nourished, she would have been less likely to need a device to help maintain her body

temperature. With regard to the pressure relief algorithm, the only information that we could find is one unpublished trial of three patients, which revealed pressures of up to 200 mmHg (measurement limited because of 200 mmHg as the maximum range of calibration).

Although the Allon system may help maintain normothermia, it may do so at some risk to patient well-being.

**Bhargavi Gali, M.D., \* James Y. Findlay, F.R.C.A., David J. Plevak, M.D.** \* Mayo Clinic, Rochester, Minnesota. [gali.bhargavi@mayo.edu](mailto:gali.bhargavi@mayo.edu).

(Accepted for publication September 28, 2003.)

Anesthesiology 2004; 100:748

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams &amp; Wilkins, Inc.

## The Perioperative Use of Cyclooxygenase-2 Selective Nonsteroidal Antiinflammatory Drugs May Offer a Safer Alternative

*To the Editor:*—We read with interest the excellent review article of randomized, controlled trials involving the effects of nonsteroidal antiinflammatory drugs (NSAIDs) on bleeding after tonsillectomy.<sup>1</sup> Although the results of this meta-analysis suggest “that the use of NSAID therapy after tonsillectomy should be abandoned both at the hospital and at home,”<sup>1</sup> we must remind the readers that the perioperative use of cyclooxygenase (COX)-2 selective NSAIDs may offer a safer alternative in the management of posttonsillectomy pain. Previous data have suggested that celecoxib,<sup>2</sup> rofecoxib,<sup>3</sup> and valdecoxib<sup>4</sup> have analgesic effects similar to conventional NSAIDs when used for acute pain. Further, because platelets express only COX-1 and are incapable of expressing COX-2,<sup>5</sup> selective COX-2 inhibitors do not inhibit platelet function. We have found that the preoperative administration of rofecoxib possesses a more favorable pharmacokinetic profile than the other COX-2 selective NSAIDs in the management of pediatric tonsillectomy pain. Rofecoxib provides onset of clinical analgesia within 27 min<sup>6</sup> and has an elimination half-life of 17.5 h; therefore, it can be administered once daily.<sup>3</sup> Rofecoxib is available as a strawberry-flavored oral suspension (containing 12.5 mg or 25 mg of rofecoxib per 5-ml solution), which makes pediatric dose titration easy to accomplish.

We recently evaluated the analgesic efficacy and safety of administering rofecoxib (1 mg/kg) prior to pediatric tonsillectomy.<sup>7</sup> This study revealed no significant increase in measured intraoperative surgical bleeding or in the likelihood of reoperation for bleeding. Furthermore, the preoperative administration of rofecoxib resulted in a significant decrease in postoperative pain and more than a threefold reduction in the incidence of postoperative nausea and vomiting. The reduction in postoperative nausea and vomiting may be attributable to either the improved analgesic efficacy of rofecoxib or to its centrally mediated action. It has been demonstrated in an animal model that activation of the medullary vomiting center involves prostaglandins, and the pre-emptive administration of COX inhibitors significantly decreased lipopolysaccharide-induced emesis.<sup>8</sup> NSAIDs with significant penetration into the central nervous system may be advantageous in reducing postoperative nausea and vomiting. Previous studies in rats have revealed that 35% of rofecoxib plasma concentrations penetrated into

the cerebrospinal fluid<sup>9</sup>; this relative penetration into the central nervous system was independent of dose ( $\leq 150$  mg/day).<sup>10</sup>

Therefore, we believe the perioperative administration of rofecoxib, a selective COX-2 inhibitor, may offer significant advantageous over conventional NSAIDs in the management of tonsillectomy pain.

**Scott S. Reuben, M.D.,\* Neil R. Connelly, M.D. \*** The Baystate Medical Center and the Tufts University School of Medicine, Springfield, Massachusetts. scott.reuben@bhs.org.

### References

1. Marret E, Flahault A, Samama C-M, Bonnet F: Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy: Meta-analysis of randomized, controlled trials. *ANESTHESIOLOGY* 2003; 98:1497-502
2. Clemett D, Goa KL: Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. *Drugs* 2000; 59:957-80
3. Barden J, Edwards JE, McQuay HJ, Moore RA: Single-dose rofecoxib for acute postoperative pain in adults: A quantitative systematic review. *BMC Anesthesiology* 2002; 2:4
4. Ormrod D, Wellington K, Wagstaff AJ: Valdecoxib. *Drugs* 2002; 62:2059-71
5. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal antiinflammatory drugs. *J Biol Chem* 1993; 268:6610-14
6. Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins TW, Geba GP: Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial. *Clin Ther* 2001; 23:1446-55
7. Joshi W, Connelly NR, Reuben SS, Wolkenhaar M, Thakkar N: Evaluation and safety of administering rofecoxib for postoperative pain management. *Anesth Analg* 2003; 97:35-8
8. Girod V, Dapzol J, Bouvier M, Grelot L: The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets. *Neuropharmacology* 2002; 42:428-36
9. Buvaendran A, Luk P, Kroin JS, Rodger IW, McCarthy RJ: Central nervous system penetration of rofecoxib, a selective COX-2 inhibitor, in rats (abstract). *ANESTHESIOLOGY* 2001; 95:A-868
10. Buvaendran A, Kroin JS, Luk P, Rodger IW, McCarthy RJ: Blood-brain barrier penetration of oral rofecoxib, a selective COX-2 inhibitor in dogs (abstract). *ANESTHESIOLOGY* 2002; 96:A-465

(Accepted for publication October 29, 2003.)

Anesthesiology 2004; 100:748-9

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams &amp; Wilkins, Inc.

## Effects of Postoperative Nonsteroidal Antiinflammatory Drugs on Bleeding Risk after Tonsillectomy

*To the Editor:*—As stated by Marret *et al.*,<sup>1</sup> posttonsillectomy hemorrhage (PTH) can be life-threatening, and an incidence of perhaps 4,500 per year in the United States with a reoperation rate of 1-5.5% is not insignificant, particularly when associated with concerns surrounding the administration of general anesthesia under such circumstances. Nonsteroidal antiinflammatory drugs (NSAIDs) are, however, now widely used not only in the operating room and ward but also at home, and they are widely believed to be safe and effective. Unfortunately, Marret *et al.* considered just seven investigations that satisfied their chosen criteria, none of which in fact reported a significant difference between the groups studied. Simply combining the results of these into a single analysis to create the reported result does not provide an adequate answer to the concerns expressed. In addition, anesthesiologists are aware that the chosen operative technique, together with the skill and experience of the operating surgeon, can be of significant importance. The total number of patients in the seven studies is small,

with marked variability, including the NSAID chosen, the number of doses administered, the surgery undertaken, and whether a primary or secondary hemorrhage occurred. An additional qualifying study was not included.<sup>2</sup>

In 1984, Carrick<sup>3</sup> reported the potential adverse consequence of increased risk by salicylate administration on platelet function when PTH occurred in 14 of 359 patients *versus* just 1 of 353 patients receiving acetaminophen. NSAIDs, including aspirin (acetylsalicylic acid), inhibit platelet cyclooxygenase and prolong bleeding time by preventing the biosynthesis of thromboxane A<sub>2</sub>, leading to reduced platelet aggregation. NSAIDs are very widely used, and because they are available without prescription many patients take them perioperatively. To overcome this problem, the New York Eye and Ear Infirmary has instructed patients not to use aspirin or products containing aspirin, as well as other NSAIDs, for at least 7 to 10 days before and after surgery.<sup>4</sup> This, as well as the standard of specialist medical care, is

**Table 1. Patients Undergoing Tonsillectomy at Glan Clwyd Hospital**

Year	Patients (No.)	PTH		NSAID		Senior Surgeon (%)	Senior Anesthetist (%)
		No.	%	No.	%		
1991	596	0	0	91	15.3	28.5	59.4
1992	637	4	0.6	136	21.4	38.8	60.6
1993	510	4	0.8	92	18.0	32.4	65.3
1994	545	2	0.4	57	10.5	21.5	63.3
1995	573	2	0.4	143	25.0	17.1	46.6
1996	572	6	1.0	104	18.2	22.7	46.7
1997	519	5	1.0	166	32.0	19.1	54.7
1998	526	2	0.4	221	42.0	17.7	58.0
1999	456	5	1.1	384	84.2	40.1	42.5
2000	451	5	1.1	262	58.1	19.7	54.7
2001	313	9	2.9	181	57.8	28.8	47.9
2002	151	2	1.3	110	72.9	41.1	68.2

Senior surgeon and senior anesthetist are trained and experienced specialists.

NSAID = nonsteroidal antiinflammatory drug administered intraoperatively; PTH = posttonsillectomy hemorrhage requiring reoperation.

reflected in their reported low incidence for PTH of 0.9% between 1992 and 1996.

Postoperative nausea and vomiting is also a relevant contributory factor. When compared with opioids, the value of NSAIDs in reducing this and avoiding the need for antiemetic administration is borne out by the only statistically significant difference reported in one of the seven included studies.<sup>5</sup>

Since the late 1980s, the first author's practice has been to administer diclofenac for pain control parenterally at the time of surgery, initially alone but subsequently together with morphine (after the now widely adopted combination had been shown to yield significant benefit). An initial audit for the years 1991 to 1994, when 2,136 tonsillectomies were performed in our hospital, revealed 10 cases requiring a return to the operating room for control of PTH (0.47%). Of the 378 patients who had received NSAIDs intraoperatively, only 1 was included in the 10 cases reported. These results suggested the practice to be safe but are in marked contrast to those subsequently published by Robinson and Ahmed<sup>6</sup> describing a 5.5% incidence of PTH following the administration of diclofenac at induction *versus* 0.7% in controls. We have now retrospectively examined the relevant data contained in our operating room management system (ORSOS<sup>®</sup>; Per-Se Technologies, Atlanta, Georgia) for the years 1991 to 2002; these are presented in table 1.

The recorded incidence of PTH requiring reoperation is reassuringly low over the whole period except for the year 2001 (2.9%). Our figures do not suggest that the experience of either surgeon or anesthesiologist is a critical factor. We have no specific record of the frequency of use of NSAIDs in the postoperative period, but we know that they have been and continue to be widely prescribed. Our data could be interpreted as showing a weak relationship between the frequency of intraoperative use and PTH. The conclusion of Marret *et al.*<sup>1</sup> that postoperative conventional NSAIDs increase the risk of reoperation for hemostasis and should not be used after tonsillectomy is too broad; it

ignores the benefits provided by a reduction in both postoperative nausea and vomiting and postoperative pain, which themselves may contribute to an increased incidence of PTH. The effects on platelet function can be of long duration and would be expected to follow even a single dose given perioperatively. Administration at or before the time of surgery may beneficially allow hemostasis to be secured while the drug is active. This study has, however, usefully served to signal the urgent need for the performance of further randomized double-blind trials with both NSAID administration and surgical factors tightly controlled in an effort to bring clarity to this issue. NSAIDs were effective in these patients, and the cyclooxygenase-2 inhibitors are currently being promoted for perioperative use.

**Alfred P. J. Lake, B.Sc., M.B.B.S., F.F.A.R.C.S., \* Magdi Khater, M.B., Ch.B., M.Sc., F.R.C.A.** \* Glan Clwyd Hospital, Denbighshire, United Kingdom. apjlake@aol.com.

## References

1. Marret E, Flahault A, Samama C-M, Bonnet F: Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy: Meta-analysis of randomized, controlled trials. *ANESTHESIOLOGY* 2003; 98:1497-502
2. Kokki H, Salonen A: Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children. *Paediatr Anaesth* 2002; 12:162-7
3. Carrick DG: Salicylates and posttonsillectomy haemorrhage. *J Laryng Otol* 1984; 98:803-5
4. McKenna M: Postoperative tonsillectomy/adenoidectomy hemorrhage: A retrospective chart review. *ORL Head Neck Nurs* 1999; 17:18-21
5. St Charles CS, Matt BH, Hamilton MM, Katz BP: A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. *Otolaryngol Head Neck Surg* 1997; 117:76-82
6. Robinson PM, Ahmed I: Diclofenac and posttonsillectomy haemorrhage. *Clin Otolaryngol* 1994; 19:344-5

(Accepted for publication October 29, 2003.)

## Nonsteroidal Antiinflammatory Drugs and Hemorrhage following Tonsillectomy: Do We Have the Data?

*To the Editor:*—Marret *et al.* provided a meta-analysis of nonsteroidal antiinflammatory drugs (NSAIDs) and bleeding risk after tonsillectomy using return to the operating room as their primary endpoint.<sup>1</sup> The authors carefully reviewed the literature and selected seven articles for inclusion.<sup>2-8</sup> We are concerned that the conclusions reached are

invalid and that the wording in the current Marret *et al.* article<sup>1</sup> provides fodder for lawyers without adequate scientific knowledge to support these admonitions.

The authors have combined repeated single-dose intramuscular administration, continuous infusion, and chronic administration of



**Table 1. Bleeding Leading to Reoperation**

Drugs		Bleeding Control	< 24 h NSAIDs	Bleeding Control	> 24 h NSAIDs
Bailey <sup>3</sup>	Ketorolac IM × 24 h (adults)	0/43	0/37	1/43	2/37‡
Gunter <sup>5</sup>	Ketorolac IV × 1 dose	0/47	1/49	0/47	1/49
Harley <sup>8</sup>	Ibuprofen × 2 wk	0/11	0/16	0/11	2/16
Rømsing <sup>4</sup>	Ketorolac IV × 1 dose	0/15	1/15*	Unknown	
St. Charles <sup>7</sup>	Ibuprofen × 2 wk	0/55	1/55†	Unknown	
Solonen <sup>14</sup>	Ketorolac × 24 h; infusion × 24 h (adults)	0/25	1/40	Unknown	
Sutters <sup>6</sup>	Ketorolac IM × 1 dose	0/42	0/45	0/42	0/45
Total		0/198	4/257§	1/198	5/257

Date are expressed as numbers.

\* Time not described: the first 15 patients were not included because five hemorrhages were attributed to poor surgical technique. † Patient returned to the operating room because of lack of cooperation. ‡ Likely that bleeding occurred more than 24 h after surgery. § chi-square  $P = 0.209$  (underpowered with  $\alpha < 0.8$ ).

IM = intramuscularly; IV = intravenously; NSAID = nonsteroidal antiinflammatory drug.

NSAIDs. Unlike aspirin, the effects of most NSAIDs on platelet function are very short-lived. For pediatric patients, the half-lives of ketorolac and ibuprofen are approximately 2 h and 1.5 h, respectively.<sup>9,10</sup> Because significant effects on platelet function are reversible and related in part to a blood concentration of NSAIDs, virtually no antiplatelet effect would be present after 5 to 6 drug half-lives. Therefore, any bleeding attributable to single doses of these medications would have to occur in the immediate postoperative period, and certainly within the first 24 h.<sup>11,12</sup> Hemorrhage that occurs after 24 h is unlikely to be caused by these medications unless they are administered after hospital discharge; we do not know if this is different with infusions or intramuscular administration.

When examining the duration of treatment (table 1 of the Marret *et al.* review), studies by St. Charles *et al.*<sup>7</sup> and Harley and Dattolo<sup>8</sup> involved patients who received treatment for 2 weeks. Both patients who had bleeding in the Harley and Dattolo study did so 2 to 7 days after the operation, so it is possible that their bleeding could be attributed either to the continued use of the NSAIDs or to the loss of eschar at 5–10 days. The patient in the St. Charles *et al.*<sup>7</sup> study returned to the operating room because of lack of cooperation.

Two studies (Salonen *et al.*<sup>2</sup> and Bailey *et al.*<sup>3</sup>) allowed administration of ketorolac for the first 24 h. In the Bailey *et al.* study (intramuscular × 24 h), there was a higher incidence of bleeding in the ketorolac group; however, on average, incidence of bleeding occurred on day 4, thus suggesting that bleeding had nothing to do with the administration of ketorolac. One adult patient in the Salonen *et al.* study (24 h infusion) experienced bleeding 14 h after surgery, which could be attributable to the NSAIDs.

The main studies of interest are the articles (Gunter *et al.*,<sup>5</sup> Rømsing *et al.*,<sup>4</sup> and Sutters *et al.*<sup>6</sup>) involving single-dose administration after the end of the procedure. One patient in the Gunter *et al.* study returned to the operating room on postoperative day 5; that patient's bleeding should not be attributed to the NSAIDs. In the Rømsing *et al.* study, 5 of the first 15 patients experienced bleeding (divided between placebo, presurgical, and postsurgical ketorolac administration), and all were operated on by the same surgeon. After eliminating that surgeon's participation in the study, only 1 of the next 45 patients required reoperation for bleeding. The time of reoperation was not described.

When examining the timing of the bleeding that was significant enough to require reoperation (the primary endpoint of the Marret *et al.* analysis), it appears that nearly half of the cases presented should not attribute bleeding directly to NSAIDs. Rather, the bleeding occurred because of poor surgical technique or at a time when it was much more likely caused by dehiscence of the eschar (5–10 days after surgery). Thus, just as anesthesiologists talk about effect site half-lives for drugs such as remifentanyl, this meta-analysis should have consid-

ered the effect-site antiplatelet effects of the NSAIDs before attributing the hemorrhage to the NSAID therapy.

Marret *et al.* suggest that the use of NSAID therapy should be abandoned both in the hospital and at home in these patients. There are insufficient data to support this strong recommendation. Only 3 of 71 patients receiving ibuprofen *versus* 0 of 66 controls experienced bleeding, and some of these could have been attributed to the loss of eschar (table 1); clearly, there are insufficient numbers for analysis. Regarding single-dose administration of ketorolac, in our experience, a single dose after the operation is completed and after hemostasis is obtained has not been associated with an increased incidence of bleeding.<sup>13,14</sup> Marret *et al.* mentioned our article to describe the general incidence of bleeding, but they did not comment on the fact that the incidence of bleeding in our retrospective review of more than 300 children having a tonsillectomy did not reveal a higher incidence of hemorrhage, even though they had received ketorolac. In the Marret *et al.* analysis, the incidence of bleeding within the first 24 h after a single dose of ketorolac was 2 of 109 patients receiving ketorolac *versus* 0 of 104 controls (table 1). Again, this cohort is too small for adequate analysis.

The risk of 1 in 29 patients having hemorrhage after NSAIDs therapy as described by Marret *et al.* is a gross overstatement. At least two bleeding events were attributed to surgical technique, whereas five others occurred at a time well after the drug had been eliminated from the body. Therefore, antiplatelet effect caused by that NSAID drug was no longer present. Using the data presented comparing 0 of 198 controls *versus* 4 of 257 patients receiving NSAIDs with bleeding less than 24 h after surgery, including one patient who returned to the operating room because of lack of cooperation, the rate of bleeding is statistically insignificant ( $P = 0.209$  chi-square). A crude power analysis suggests that to demonstrate a difference with these frequencies, more than 4,000 patients would need to be studied ( $\alpha = 0.05$ , with power of 0.8) to demonstrate a difference in treatment groups.

We suggest that Marret *et al.* reexamine their data, taking into consideration the effect of the drug's half-life on platelet function. Elimination of cases in which the hemorrhage occurred beyond the period when the drug could have had antiplatelet effects, in which patients returned to the operating room because of poor surgical technique or lack of cooperation, and in which patients received the ibuprofen chronically (their bleeding could be attributable to either loss of eschar or antiplatelet effects), would allow the authors to make more accurate recommendations. We certainly acknowledge that ketorolac can cause hemorrhage if administered preoperatively or intraoperatively before hemostasis is completed, but we believe that it is a very safe analgesic when administered as a single dose after hemostasis is obtained.

Richard Dsida, M.D.,\* Charles J. Coté, M.D. \* The Feinberg School of Medicine at Northwestern University, Chicago, Illinois. R-Dsida@northwestern.edu

## References

1. Marret E, Flahault A, Samama C-M, Bonnet F: Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy: Meta-analysis of randomized, controlled trials. *ANESTHESIOLOGY* 2003; 98:1497-502
2. Salonen A, Kokki H, Tuovinen K: I. v. ketoprofen for analgesia after tonsillectomy: Comparison of pre- and postoperative administration. *Br J Anaesth* 2001; 86:377-81
3. Bailey R, Sinha C, Burgess LP: Ketorolac tromethamine and hemorrhage in tonsillectomy: A prospective, randomized, double-blind study. *Laryngoscope* 1997; 107:166-9
4. Romsing J, Østergaard D, Walther-Larsen S, Valentin N: Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. *Acta Anaesthesiol Scand* 1998; 42:770-5
5. Gunter JB, Varughese AM, Harrington JF, Wittkugel EP, Patankar SS, Matar MM, Lowe EE, Myer CM III, Willging JP: Recovery and complications after tonsillectomy in children: A comparison of ketorolac and morphine. *Anesth Analg* 1995; 81:1136-41

6. Sutters KA, Levine JD, Dibble S, Savedra M, Miaskowski C: Analgesic efficacy and safety of single-dose intramuscular ketorolac for postoperative pain management in children following tonsillectomy. *Pain* 1995; 61:145-53
7. St Charles CS, Matt BH, Hamilton MM, Katz BP: A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. *Otolaryngol Head Neck Surg* 1997; 117:76-82
8. Harley EH, Dattolo RA: Ibuprofen for tonsillectomy pain in children: Efficacy and complications. *Otolaryngol Head Neck Surg* 1998; 119:492-6
9. Dsida RM, Wheeler M, Birmingham PK, Wang Z, Heffner CL, Coté CJ, Avram MJ: Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. *Anesth Analg* 2002; 94:266-70
10. Konstan MW, Hoppel CL, Chai BL, Davis PB: Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects. *J Pediatr* 1991; 118:956-64
11. Ikeda Y: The effect of ibuprofen on platelet function in vivo. *Keio J Med* 1977; 26:213-22
12. Niemi TT, Backman JT, Syrjala MT, Viinikka LU, Rosenberg PH: Platelet dysfunction after intravenous ketorolac or propacetamol. *Acta Anaesthesiol Scand* 2000; 44:69-74
13. Agrawal A, Gerson CR, Seligman I, Dsida RM: Postoperative hemorrhage after tonsillectomy: Use of ketorolac tromethamine. *Otolaryngol Head Neck Surg* 1999; 120:335-9
14. Kokki H, Salonen: Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children. *Paediatric Anesth* 2002; 12:162-7

(Accepted for publication October 29, 2003.)

Anesthesiology 2004; 100:751-2

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

**In Reply:**—We appreciate the three comments concerning our meta-analysis on the risk of nonsteroidal antiinflammatory drugs (NSAIDs) after tonsillectomy.

Drs. Dsida and Coté suggest excluding patients who had bleeding 24 h after tonsillectomy and who received NSAIDs for less than 24 h, or patients with bleeding induced by lack of cooperation and poor surgical technique. Under these criteria, more than half of the cases of reintervention published in the original articles would be excluded.<sup>1-7</sup> Moreover, Dsida and Coté cite one controlled, double-blind, randomized trial that studied NSAIDs given within 24 h postoperatively.<sup>8</sup> This study reports two children in the postoperative ketoprofen group (n = 42) who required electrocautery to stop their bleeding. In contrast, none of children in the placebo group (n = 20) returned to the operating room. Including this study in the analysis proposed by Dsida and Coté (table 1) leads to a statistically significant risk of primary hemorrhage (0 of 218 in the control group *vs.* 6 of 299 in the NSAIDs group; *P* = 0.04, Fisher exact test). We performed an intention-to-treat analysis based on the original data.<sup>9</sup> Consequently, all patients included in the study were analyzed according to the groups to which they were originally randomly assigned, whatever the duration of treatment or the cooperation of the patient or surgeon.<sup>1-7</sup> The intention-to-treat approach maintains a comparable distribution of established groups of patients that are similar apart from the randomized factor.<sup>10</sup> Excluding randomized patients after their inclusion in the trial may lead to bias due to a modification of allocation. All of the trials included in our meta-analysis were randomized. Therefore, in our meta-analysis the distribution of patients was similar between the different groups except for the use of NSAIDs. When Drs. Dsida and Coté claim that NSAIDs have no effect, it means that the risk of bleeding should be similar whatever the NSAID dose, duration of treatment, or name of the surgeon. Moreover, they cannot deny that short-term administration of NSAIDs may have long-term consequences. NSAIDs inhibit cyclooxygenase, resulting in an inhibition of platelet aggregation. Thus, NSAIDs given immediately in the postoperative period may increase the importance of hematoma induced by the tonsil dissection. The eschar situated in the soft tissue near the tonsillar bed may be more important with the use of NSAIDs than with a control treatment and may explain secondary bleeding related to the loss of eschar of tonsillar fossa. The postoperative administration of NSAIDs, whatever the duration of treatment, may consequently increase the risk of early and late reoperation. Excluding patients who had later bleeding after a single dose

of NSAIDs may underestimate the effect of NSAIDs on bleeding in the final analysis. In one of the studies, Dsida and Coté also suggested the exclusion patients who were operated on by the same surgeon and who were especially at risk for complications.<sup>4</sup> However, the same surgeon also operated on other randomized patients. This seems to be an unacceptable handling of the data that may introduce some bias into the analysis. Excluding cases is contrary to the principle of intention-to-treat.<sup>10,11</sup> The exclusion of patients in randomized controlled trials has been recognized as an overestimation of the benefit of treatment in comparison with the intention-to-treat analysis, based on the submitted reports.<sup>12</sup> Similarly, the exclusion of patients who experienced adverse effects such as hemorrhage may underestimate the risk of NSAIDs use after a tonsillectomy.

Drs. Lake and Khater report a retrospective cohort of patients scheduled for tonsillectomy at Glan Clwyd Hospital between 1991 and 2002. Interestingly, their data document a clear increase in the incidence of reoperation after tonsillectomy related to the increased number of patient who used NSAIDs. When NSAIDs were administered to less than half of the patients (from 1991 to 1998), the incidence of reoperation was less than 1%. In contrast, the incidence was greater than 1% during the past 4 yr, and as high as 2.9% in 2001 when NSAIDs were used in more than 50% of the patients. Lake and Khater also advocated that NSAIDs decrease the incidence of postoperative nausea and vomiting. Although this is a reasonable assertion, alternative treatments devoid of effect on hemostasis may be more appropriate in this setting. In fact, other treatments such as ondansetron<sup>13</sup> or dexamethasone<sup>14</sup> reduce postoperative nausea and vomiting and postoperative pain.<sup>15</sup> Physicians also have cyclooxygenase-2 inhibitors to relieve postoperative pain and prevent postoperative nausea and vomiting, as suggested by Joshi *et al.*<sup>16</sup> We agree that selective inhibitors of cyclooxygenase could be an interesting alternative because of their lack of effect on platelet aggregation. In contrast, anesthesiologists do not have such pharmacologic alternatives to stop bleeding after a tonsillectomy.

Dsida and Coté and Lake and Khater point out a randomized, double-blind, controlled trial that compared postoperative NSAIDs analgesia with preoperative NSAIDs or placebo,<sup>8</sup> published in 2002 after the completion of our own research in 2001.<sup>8</sup> In this trial, two children in the postoperative NSAIDs group returned to the operating room because of postoperative bleeding. We updated our meta-analysis to include the result of this last study. A significant increase in reoperation



was still documented with the use of NSAIDs (odds ratio: 4.0; 95% confidence interval: 1.4, 11.3;  $P = 0.009$ ;  $P = 0.98$  for the heterogeneity test).

Finally, Drs. Lake and Khater concluded that urgent, randomized, double-blind trials are needed to clarify the risk of reoperation with NSAIDs use. In fact, there is now sufficient evidence to demonstrate an increased risk of bleeding after tonsillectomy with NSAIDs. Regarding this risk of reoperation, we consider that the use of NSAIDs should be abandoned.

**Emmanuel Marret, M.D.,\* Francis Bonnet, M.D. \* Tenon Teaching Hospital, Paris VI University, Paris, France.**  
emmanuel.marret@tnn.ap-hop-paris.fr

## References

1. Bailey R, Sinha C, Burgess LP: Ketorolac tromethamine and hemorrhage in tonsillectomy: A prospective, randomized, double-blind study. *Laryngoscope* 1997; 107:166-9
2. Gunter JB, Varughese AM, Harrington JF, Wittkugel EP, Patankar SS, Matar MM, Lowe EE, Myer CM III, Willing JP: Recovery and complications after tonsillectomy in children: A comparison of ketorolac and morphine. *Anesth Analg* 1995; 81:1136-41
3. Harley EH, Dattolo RA: Ibuprofen for tonsillectomy pain in children: Efficacy and complications. *Otolaryngol Head Neck Surg* 1998; 119:492-6
4. Romsing J, Ostergaard D, Walther-Larsen S, Valentin N: Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. *Acta Anaesthesiol Scand* 1998; 42:770-5
5. Salonen A, Kokki H, Tuovinen K: I. v. ketoprofen for analgesia after tonsillectomy: Comparison of pre- and postoperative administration. *Br J Anaesth* 2001; 86:377-81
6. St Charles CS, Matt BH, Hamilton MM, Katz BP: A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. *Otolaryngol Head Neck Surg* 1997; 117:76-82
7. Sutters KA, Levine JD, Dibble S, Savedra M, Miaskowski C: Analgesic efficacy and safety of single-dose intramuscular ketorolac for postoperative pain management in children following tonsillectomy. *Pain* 1995; 61:145-53
8. Kokki H, Salonen A: Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children. *Paediatr Anaesth* 2002; 12:162-7
9. Marret E, Flahault A, Samama CM, Bonnet F: Effects of postoperative, nonsteroidal, antiinflammatory drugs on bleeding risk after tonsillectomy: Meta-analysis of randomized, controlled trials. *ANESTHESIOLOGY* 2003; 98:1497-502
10. Montori VM, Guyatt GH: Intention-to-treat principle. *CMAJ* 2001; 165:1339-41
11. Armitage P, Berry G, Matthews JNS: *Statistical Method in Medical Research*, 4th ed. Oxford, Blackwell Science, 2002, p 642
12. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence based medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. *BMJ* 2003; 326:1171-3
13. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ: Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials. *ANESTHESIOLOGY* 1997; 87:1277-89
14. Henzi I, Walder B, Tramer MR: Dexamethasone for the prevention of postoperative nausea and vomiting: A quantitative systematic review. *Anesth Analg* 2000; 90:186-94
15. Elhakim M, Ali NM, Rashed I, Riad MK, Refat M: Dexamethasone reduces postoperative vomiting and pain after pediatric tonsillectomy. *Can J Anaesth* 2003; 50:392-7
16. Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. *Anesth Analg* 2003; 97:35-8

(Accepted for publication October 29, 2003.)

Anesthesiology 2004; 100:752

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

## Carotid Sinus Mechanical Properties

*To the Editor:*—Boyce and Peters<sup>1</sup> describe the interesting case of complete vasomotor collapse during resection of a recurrent right carotid body tumor involving the right carotid bifurcation requiring excision and autologous vein grafting. The authors suggest mechanical or electrical stimulation of the right carotid sinus nerve as the initiating event leading to vasomotor collapse. Rarely, however, does a significant increase in afferent activity from a single baroreceptor site result in the described persistent profound hypotension because of compensation from other baroreceptor sites, even in the absence of a right vagus nerve.

Alternatively, if in this patient the tumor had infiltrated the right carotid sinus wall such that no deformation (strain) of the baroreceptors could take place as can occur in severe carotid atherosclerosis,<sup>2</sup> then there would be no afferent neural input to the hindbrain from this site. Under these circumstances, the vasomotor integration centers in the hindbrain would not recognize zero input from the right carotid sinus as a legitimate null signal, particularly in the presence of normal afferent signals from other baroreceptor sites.<sup>3</sup> Subsequently, sudden significant afferent activity in the right carotid sinus nerve, either from exogenous deformation of the sinus wall or direct stimulation, would probably be interpreted as a very significant signal by the hindbrain because of the neural history from this site, resulting in the reported

dramatic decrease in blood pressure. A similar phenomenon is occasionally seen during carotid endarterectomy when severe atherosclerotic plaque is suddenly removed from the carotid sinus area.<sup>4,5</sup>

**Roger J. Bagshaw, M.D.** University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. bagshawr@uphs.upenn.edu.

## References

1. Boyce JR, Peters GE: Complete vasomotor collapse: An unusual manifestation of the carotid sinus reflex. *ANESTHESIOLOGY* 2003; 98:1285-7
2. Cox RH, Bagshaw RJ, Detweiler DK: Alterations in carotid sinus reflex control of arterial hemodynamics associated with experimental hyperlipemia in the racing greyhound. *Circ Res* 1980; 46:237-44
3. Bagshaw RJ, Barrer SJ: Effects of angioplasty upon carotid sinus mechanical properties and blood pressure control in the dog. *Neurosurgery* 1987; 21:324-30
4. Tyden G, Samnegard H, Melcher A, Thulin L: Effect of carotid endarterectomy on the antihypertensive properties of the carotid sinus reflex. *Acta Chir Scand* 1981; 147:15-7
5. Tyden G, Samnegard H, Thulin L, Muhrbeck O: Effect of carotid endarterectomy on baroreflex sensitivity in man: Intraoperative studies. *Acta Chir Scand Suppl* 1980; 500:67-9

(Accepted for publication September 23, 2003.)

## Unusual Case of Breathing Circuit Obstruction: Plastic Packaging Revisited

**To the Editor:**—Most of the preventable incidents in anesthesia practice involve human error, with breathing circuit disconnections featuring prominently. Overt equipment failures constitute a small proportion of preventable incidents, but equipment design is contributory in many categories of human error.<sup>1-4</sup> We herein report a case of a breathing circuit obstruction resulting from failure to completely remove the transparent packaging.

A 36-yr-old, 185-cm, 86-kg healthy man with no history of previous anesthesia underwent uneventful induction of general anesthesia for endoscopic sinus surgery conducted in a standard manner with midazolam, fentanyl, propofol, and vecuronium. Tracheal intubation was accomplished with an 8.0-mm-ID oral cuffed endotracheal tube. Proper endotracheal tube placement was confirmed by auscultation of bilateral breath sounds and end-tidal carbon dioxide. Endotracheal tube depth was confirmed and secured. At the request of the surgeon, the breathing circuit was briefly disconnected and the table was rotated 180 degrees. The existing 90-degree gas sampling connector was removed, and a straight gas sampling connector (SIMS Portex, Inc., Fort Myers, FL) was removed from its plastic packaging and placed in-line. Chest excursion immediately ceased and the ventilator failed to cycle. Hand ventilation with the anesthesia machine was attempted and failed. An Oxygen E-Cylinder with a Mapleson circuit (Vital Signs, Totowa, NJ) was used to ventilate the patient without difficulty with intravenous propofol infusion to maintain anesthesia. Auscultation of the chest revealed normal breath sounds. Careful inspection of the breathing circuit revealed a taut, transparent diaphragm of plastic packaging obstructing the straight connector at its interface with the breathing circuit (fig. 1). The clinician's thumb had inadvertently retained this transparent obstruction on removal from its packaging. Following removal of the obstruction, the circuit was reconnected and the case proceeded uneventfully.

In summary, we suggest that as an additional measure of safety, packaging for airway components be considered both for its visibility and potential for airway circuit obstruction (fig. 2). We contacted the manufacturer (Portex, Inc., Keene, NH) and MEDWATCH (the U.S. Food and Drug Administration Safety Information and Adverse Event Reporting Program) to alert them of our experience.

**Andrew C. Chacon, M.D., Krzysztof M. Kuczkowski, M.D.,\***  
**Ramon A. Sanchez, M.D.** \* University of California, San Diego,  
California. [kkuczkowski@ucsd.edu](mailto:kkuczkowski@ucsd.edu).

### References

- Cooper JB, Newbower RS, Long CD: Preventable anesthesia mishaps: A study of human factors. *Qual Saf Health Care* 2002; 11:277-82
- Feingold A: Carbon dioxide absorber packaging hazard (letter). *ANESTHESIOLOGY* 1976; 45:260
- Norman PH, Daley MD, Walker JR, Fusetti S: Obstruction due to retained carbon dioxide absorber canister wrapping. *Anesth Analg* 1996; 83:425-6
- Neufeld PD, Johnson DL, deVeth J: Safety of anaesthesia breathing circuit connectors. *Can Anaesth Soc J* 1983; 30:646-52

(Accepted for publication September 26, 2003.)

After numerous failed attempts to acquire a Reply to this Letter, it is being published without a response. —Michael M. Todd, Editor-in-Chief.



**Fig. 1.** Straight gas sampling connector (SIMS Portex) with plastic packaging forming an obstructive membrane.



**Fig. 2.** Straight gas sampling connector (SIMS Portex) in its original plastic packaging.

Anesthesiology 2004; 100:754

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams &amp; Wilkins, Inc.

## Revenue Gain for Academic Anesthesiology Departments if the Centers for Medicare and Medicaid Services Provide Full Reimbursement to Teaching Physicians

**To the Editor:**—Following the 1996 publication of new rules regarding payment to teaching physicians, the Centers for Medicare and Medicaid Services (then known as the Health Care Financing Administration) reduced by 50% the payments made to teaching anesthesiologists for medical direction of residents at a ratio of one faculty member to two residents. After 1996, the Centers for Medicare and Medicaid Services paid 100% of allowable charges to a teaching anesthesiologist *only* when the physician either personally performed the care or medically directed only one resident. Because resident care could not be billed to the Centers for Medicare and Medicaid Services, this change in the teaching rules resulted in a significant reduction in payments to academic anesthesiology groups.<sup>1</sup> Recently, the Centers for Medicare and Medicaid Services were asked to reexamine these teaching rules by both anesthesiology societies and Senator Hillary Clinton (written communication to Mr. Thomas Scully, April 2003).

Using data from a previously published study,<sup>2</sup> we examined the potential financial impact that a change to full reimbursement would have on two of the four academic anesthesiology groups examined in that investigation (the database for the other two groups did not identify Medicare and other payers). Groups A and D (as designated in the previous study) provided care to 2,549 and 7,096 Medicare beneficiaries undergoing surgery during the 1-yr study period. For purposes of analysis, we used the conversion factor for the Galveston, Texas, area (\$17.23) and assumed that all anesthetic procedures were performed by anesthesiologists supervising residents at a 1:2 ratio.<sup>3</sup> We calculated that the annual revenue lost by the current rules, *versus* the pre-1996 rules, was \$350,000 for group A and \$1,070,000 for group D (table 1). The estimated lost revenue per case was similar between the two groups (\$137 and \$150 for groups A and D, respectively).

If the previous rules for full payment (which are similar to the current rules applied to other medical specialties) were applied, the increase in revenue would help academic anesthesiology departments successfully meet their economic challenges.

Support was provided solely from institutional and/or departmental sources.

**Table 1. Impact of Teaching Rules on Academic Anesthesiology Departments**

	Group A	Group D
Cases (No.)	2,549	7,096
Total ASA units billed (No.)	40,600	124,100
Total allowable	\$700,000	\$2,140,000
50% not paid because of faculty supervision of resident care at 1:2 ratio	\$350,000	\$1,070,000
Revenue lost per case	\$137	\$151

Medicare cases billed in 1996 by two different academic anesthesiology departments; allowable calculated using the 2003 Galveston, Texas, conversion factor (\$17.23). Estimates are based on the assumption that all cases would be performed using the staffing model of one teaching anesthesiologist to two residents. This information is based on data from a previous study by Abouleish *et al.*<sup>2</sup>

ASA = American Society of Anesthesiologists.

**Amr E. Abouleish, M.D., M.B.A., \* Donald S. Prough, M.D., Lydia A. Conlay, M.D., Ph.D., M.B.A., Charles W. Whitten, M.D.**  
\*University of Texas Medical Branch, Galveston, Texas.  
aaboule@utmb.edu.

## References

1. Tremper KK, Barker SJ, Gelman S, Reves JG, Saubermann AJ, Shanks AM, Greenfield ML, Anderson ST: A demographic, service, and financial survey of anesthesia training programs in the United States. *Anesth Analg* 2003; 96:1432–46
2. Abouleish AE, Prough DS, Zornow MH, Hughes J, Whitten CW, Conlay LA, Abate JJ, Horn TE: The impact of longer-than-average anesthesia times on the billing of academic anesthesiology departments. *Anesth Analg* 2001; 93:1537–43
3. Biernstein K: 2003 Medicare Anesthesia Conversion Factor is \$17.05. *American Society of Anesthesiologists Newsletter* 2003; 67:23–5

(Accepted for publication October 10, 2003.)

Anesthesiology 2004; 100:754–5

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams &amp; Wilkins, Inc.

## Deviation of the Cauda Equina by Changing Position


**To the Editor:**—We have obtained interesting information about spinal puncture using magnetic resonance imaging. It is important to understand the anatomy of the cauda equina when performing spinal anesthesia. Previous studies using computed tomography or magnetic resonance imaging have shown that in the supine position, the cauda equina lies symmetrically in the dorsal subarachnoid space.<sup>1–3</sup> However, a patient is usually placed in the lateral decubitus position during spinal puncture. Thus, it is necessary to obtain detailed anatomic information about the cauda equina in the lateral decubitus position. Magnetic resonance imaging reveals interesting and important information about the anatomy of the cauda equina. In seven healthy volunteers, axial views of magnetic resonance imaging of the cauda equina during both the supine and left lateral decubitus positions were obtained and compared. In all subjects, a movement of the cauda

equina was observed by changing position. The cauda equina lay symmetrically at the dorsal side of the subarachnoid space when the patient is in the supine position (fig. 1A). However, it moved to the left side of the subarachnoid space when the patient was placed in the left lateral decubitus position (fig. 1B). Our observations are similar to those that Fink *et al.* reported in an abstract at the 1993 Annual Meeting of the American Society of Anesthesiologists (published in *ANESTHESIOLOGY* 1993; 79:A828). These results suggest that the cauda equina has considerable mobility in the cerebrospinal fluid. During the lateral decubitus position, it may dynamically move to the gravity-dependent side. This phenomenon may alter our thought on spinal anesthesia. First, we should care about cauda equina syndrome. If a spinal needle is inserted downward in the lateral decubitus position, it may increase the possibility of injury to the cauda equina. Second, it is necessary to consider the specific gravity of local anesthetics for spinal anesthesia. Differences in anesthetic effects between hyperbaric and

Support was provided solely from institutional and/or departmental sources.

Anesthesiology, V 100, No 3, Mar 2004





**Fig. 1.** Axial view of the cauda equina. Magnetic resonance imaging (T2 weighted, spin echo, TR 2000/TE, 100 ms) at L2–3 level in the same subject were obtained in the supine position (A) and in the left lateral decubitus position (B). After changing position, the cauda equina markedly moved to the left side of the subarachnoid space. L = left; R = right.

hypobaric local anesthetics may contribute to the deviation of the cauda equina by changing position. Although additional investigations concerning the anatomy of the cauda equina are necessary, this observation transforms our knowledge about spinal anesthesia.

**Tetsuo Takiguchi, M.D., Ph.D., Shigeki Yamaguchi, M.D., Ph.D.,\* Yasuhisa Okuda, M.D., Ph. D., Toshimitsu Kitajima, M.D., Ph.D.** Dokkyo University School of Medicine, Tochigi, Japan. shigeki@dokkyomed.ac.jp

## References

1. Monajati A, Wayne WS, Rauschnig W, Ekholm SE: MR of the cauda equina. *Am J Neuroradiol* 1987; 8:893–900
2. Wall EJ, Cohen MS, Massie JB, Massie JB, Rydevik B, Garfin SR: Cauda equina anatomy. I: Intrathecal nerve root organization. *Spine* 1990; 8:1244–7
3. Cohen MS, Wall EJ, Kerber CW, Abitbol JJ, Garfin SR: The anatomy of the cauda equina on CT scans and MRI. *J Bone Joint Surg Br* 1991; 73:381–4

(Accepted for publication September 18, 2003.)


Anesthesiology 2004; 100:755–6

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

## Novel Breathing Circuit Architecture: New Consequences of Old Problems

**To the Editor:**—New anesthesia machines incorporate novel designs of familiar components to provide additional functionality. The current literature and the U.S. Food and Drug Administration's MAUDE database\* contain periodic reports of difficulties in operating this modern equipment.<sup>1,2</sup> The onus is on anesthesiologists to remain vigilant to possible new problems with this equipment and to new manifestations of old problems.<sup>3</sup> We recently experienced a condition in which the design of the Dräger Fabius GS (Dräger Medical Inc., Telford, PA) anesthesia machine's breathing circuit exposed a loss of redundancy that was heretofore present in anesthesia machines.

After induction of anesthesia, mechanical ventilation and 2% desflurane in nitrous oxide/oxygen were provided with a Dräger Fabius GS anesthesia machine. Set gas flows were 2 l/min of nitrous oxide and 1 l/min of oxygen. The anesthesia machine had been completely checked according to the manufacturer's directions immediately before the case. This included leak tests of the circuit, breathing bag, and ventilator, all of which showed satisfactory results. Immediately after induction, we realized that the patient was latex-allergic and replaced the breathing bag with a nonlatex bag. A few minutes later, we noted that the breathing bag was empty. This is never a normal condition with the Fabius GS, as this machine has a piston ventilator and uses the breathing bag as the gas reservoir during mechanical ventilation.<sup>3</sup> A scan of the monitors revealed that the circuit gas sampled by the gas analyzer at the Y piece contained 23% oxygen, 52% nitrous oxide, and 1.3% desflurane, all lower than the machine was set to deliver (fig. 1). The oxygen sensor on the machine also showed that less oxygen was being delivered than the machine was set for. We inferred that the machine was entraining room air, as it is designed to do under conditions of insufficient fresh gas flow, but this appeared to be inconsistent with the 3-l flows set on the machine, and we immediately suspected a breathing circuit leak. We disconnected the patient from the anesthesia machine, switched to manual ventilation mode, closed the adjustable pressure-limiting valve, and attempted to pressurize the circuit. This revealed a large hole hidden in the folds of the nonlatex



**Fig. 1.** Anesthesia machine settings during the event described. Inset shows contemporaneous gas analyzer readings. The difference was due to room air entrained through a large hole in the breathing bag.

breathing bag. The breathing bag was quickly replaced, the circuit was successfully pressure-tested, and mechanical ventilation and delivery of anesthetics were resumed. Thereafter, gas monitor values were consistent with machine settings. Afterwards, the patient denied recall of intraoperative events.

This is not the first report of a sudden inability to pressurize the breathing circuit of the Fabius GS. In 2002, several reports were made to the Food and Drug Administration of an inability to pressurize the breathing circuit, sometimes after successfully completing a leak test. This problem was traced by Dräger's engineers to a small change in a proven design, and the problem has been definitively addressed.

The Dräger Fabius GS uses a piston-driven ventilator, and the piston is not the breathing circuit gas reservoir. Instead, the breathing bag

Support was provided solely from institutional and/or departmental sources.

\* Available at: [www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/Search.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/Search.cfm). Accessed June 1, 2003.

serves as the reservoir during both mechanical and manual ventilation. Breathing bag failure compromised the function of our anesthesia machine in both ventilation modes: the inability to pressurize the circuit in manual mode and decreased oxygen and anesthetic concentrations in mechanical mode.

Our failure was not so catastrophic that the patient could not be ventilated (at least mechanically), and it had nothing to do with the anesthesia machine itself. Adequate mechanical ventilation continued throughout the event. However, the anesthesia machine entrained room air presumably freely through the hole in the breathing bag. This path of air entrainment explains another important feature of this event: no alarms sounded to alert clinicians of the failure.

The Fabius GS has a "low fresh gas flow" alarm to alert users that insufficient gas is entering the circuit to make up for removal due to uptake and leaks. With inadequate fresh gas flow, the piston empties the breathing bag and then room air is entrained *via* a one-way valve into the piston chamber so that the ventilator delivers the set tidal volume. A small negative pressure is generated when the ventilator attempts to draw from an empty breathing bag, triggering the alarm. In our case, the circuit was always in continuity with the atmosphere because of the large hole in the breathing bag, no negative pressure was developed, and no alarms sounded, but room air was entrained. Instead, we detected and corrected a massive circuit leak (induced after machine checkout) by observation of a constellation of inconsistencies. Despite improved alarm systems, previously secondary monitors such as agent analyzers are sometimes the only alerts to impending failures (in this case, awareness).<sup>4</sup>

Anesthesiology 2004; 100:756

**In Reply:**—The letter by Sandberg and Kaiser describes the entrainment of room air through a hole in a reservoir bag placed on a Fabius GS anesthesia machine (Draeger Medical Inc., Telford, PA) after the machine check had been completed. Before any adverse event could occur, the problem was identified by noting that the reservoir bag was not filling with gas during mechanical ventilation and that the concentrations of oxygen and anesthetic in the circuit were less than the concentrations set to be delivered by the machine. This report underscores several important issues concerning the safe use of not only a new design of an anesthesia machine like that of the Fabius GS but also of all anesthesia machines.

Machine checkout is a fundamental aspect of the strategy to use any anesthesia machine safely. Having confirmed proper functioning of the anesthesia machine prior to induction, Sandberg and Kaiser made an appropriate decision to avoid exposing the latex-allergic patient to latex by changing to a bag that did not contain latex. Because the procedure was already under way when the bag was changed, they did not have an opportunity to repeat the machine checkout, which would have identified a leak in the system. Once the preuse checkout is completed, changing or disconnecting any components of the circuit should be avoided unless the checkout can be repeated prior to use.

Another important point is the value of training users to understand the proper functioning of the anesthesia machine. The Fabius GS is designed with the reservoir bag as part of the circuit during mechanical ventilation so that fresh gas can accumulate in the bag during inspiration. The intent of this design is to improve the accuracy and consistency of tidal volume delivery by eliminating the interaction between fresh gas flow and tidal volume characteristic of a traditional anesthesia machine design. The authors had been trained to understand that the reservoir bag on the Fabius GS is an indicator of adequate fresh gas flow, just as the bellows is on a traditional anesthesia machine. After

Relative to older designs, subtle changes in the external operation of the Fabius GS conceal radical internal changes that both add functionality and completely alter its response to failure conditions. The use of a piston ventilator with room air entrainment as a backup gas source is safe because it ensures adequate ventilation. However, this design could lead to awareness<sup>5</sup> without the use of agent analysis or some measure of anesthetic depth, and is also of concern when considering the use of the machine to care for patients dependent on high inspired oxygen concentrations.

**Warren S. Sandberg, M.D., Ph.D.,†** **Sheila Kaiser, C.R.N.A.**  
† Massachusetts General Hospital, Boston, Massachusetts.  
wsandberg@partners.org.

## References

1. Kimatian SJ: With technology comes responsibility: Intraoperative failure of an anesthetic vaporizer. *ANESTHESIOLOGY* 2002; 96:1533-5
2. Barahal D, Sims C: Ventilator failure during use of a new anesthesia machine. *ANESTHESIOLOGY* 2001; 95:568-9
3. Olympio MA: Modern anesthesia machines offer new safety features. *Anesthesia Patient Safety Foundation Newsletter* 2003; 18:24-7
4. Kennedy RR, French RA: A breathing circuit disconnection detected by anesthetic agent monitoring. *Can J Anaesth* 2001; 48:847-9
5. Inoue S, Sakamoto T, Kitaguchi K, Furuya H: Awareness due to disconnection from the fresh gas supply: Why could ventilation be achieved in spite of disconnection from the fresh gas supply? *Acta Anaesthesiol Sin* 2000; 38:85-8

(Accepted for publication September 17, 2003.)

© 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

the reservoir bag was changed they continued with mechanical ventilation, but they quickly recognized that a problem existed when the reservoir bag did not fill. User training has become especially important with the development of new anesthesia machine designs, because indicators of proper functioning are different from traditional machine technology.

The importance of monitoring technology to patient safety has been emphasized repeatedly in the literature, and this report is just one more example. Indeed, observation of oxygen and anesthetic vapor concentrations led Sandberg and Kaiser to suspect that air was entering the breathing circuit. No matter how advanced anesthesia delivery systems become, monitoring the concentration of gases and vapors delivered to the patient will remain fundamental to confirming that the patient is receiving what the anesthesia provider intends to deliver.

To understand how the Fabius GS design facilitated the identification of the hole in the reservoir bag, it is useful to speculate about the implications of a similar situation when using a traditional anesthesia machine design. On a traditional anesthesia machine, the reservoir bag is excluded from the breathing circuit during mechanical ventilation. Had the bag been changed after induction and the start of mechanical ventilation on a traditional anesthesia machine, the hole in the bag might not have been recognized until the end of the procedure, when manual positive pressure ventilation was needed to facilitate emergence. The Fabius GS design likely led to an earlier recognition of the problem, because the bag did not fill with gas as expected immediately after it was changed.

**Jeffrey M. Feldman, M.D., M.S.E.** Draeger Medical Inc., Telford, Pennsylvania. feldmanj@draegermed.com.

(Accepted for publication September 17, 2003.)